Onconano Medicine Inc. raised around $50 million in series B financing to accelerate the momentum of its technology designed to diagnose and treat cancer with high specificity. The biotech company’s nanosensor works by reacting to low pH and illuminates cancer like a lightbulb, distinguishing cancerous tissue from healthy tissue. This is intended to make it easier for surgeons to remove cancer cells while leaving healthy, functional tissue intact.
The company’s product candidates exploit pH as a biomarker to help patients across the continuum of cancer care, from diagnosis to treatment, and have been gaining momentum in recent years. They include solid tumor therapeutics, agents for real-time image-guided surgery, as well as a platform of product candidates that activate and guide the immune system to target cancer...(read more)
The company’s product candidates exploit pH as a biomarker to help patients across the continuum of cancer care, from diagnosis to treatment, and have been gaining momentum in recent years. They include solid tumor therapeutics, agents for real-time image-guided surgery, as well as a platform of product candidates that activate and guide the immune system to target cancer...(read more)
RSS Feed